학술논문

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan
Document Type
Article
Source
In The Lancet Haematology June 2017 4(6):e283-e292
Subject
Primary Research
Articles
Language
ISSN
2352-3026